Photo of Brett A. Postal

Brett A. Postal has a wide range of experience across intellectual property law with a particular focus on the chemical, pharmaceutical, biological, and life science technologies. Mr. Postal’s work encompasses a broad spectrum of intellectual property matters, including patent litigation (in both district and appellate court), post-grant proceedings, client counseling, patent prosecution, and opinion work.

In MaxLinear, Inc. v. CF Crespe LLC, the Federal Circuit recently confirmed that issue preclusion applies to administrative agency decisions, including those from the Patent Trial and Appeal Board (“PTAB”) in IPR proceedings.  In MaxLinear, Inc., the Federal Circuit was presented with the appeal of a PTAB decision upholding the patentability of the

On October 5, 2017, the Patent Trial and Appeal Board (“Board”) issued a final written decision in an inter partes review proceeding filed by Neptune Generics, LLC (“Neptune”) challenging the patentability of the claims in Eli Lilly & Co.’s Patent No. 7,772,209 (“the ’209 patent”).  The Board held that Neptune failed to establish that claims